Real-World Economic Impact of OnabotulinumtoxinA in Patients with Chronic Migraine

被引：0
|
作者：
Rothrock, John [1 ]
Bloudek, Lisa [2 ]
Houle, Timothy [3 ]
Andress-Rothrock, Diane [4 ]
Hanlon, Christopher [1 ]
Varon, Sepideh [2 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[2] Allergan, Irvine, CA USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Univ Alabama Birmingham, Headache Treatment & Res Program, Birmingham, AL USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P03233
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Andrew M. Blumenfeld
    Benjamin M. Frishberg
    Jack D. Schim
    Ashley Iannone
    Gary Schneider
    Larisa Yedigarova
    Aubrey Manack Adams
    Pain and Therapy, 2021, 10 : 809 - 826
  • [32] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (10): : 1119 - 1128
  • [33] Real-world persistence rates for onabotulinumtoxinA versus CGRP mAbs among patients with chronic migraine: An analysis of electronic health record data
    Blumenfeld, A. M.
    Lee, J.
    Knievel, K.
    McVige, J. W.
    Bogdanov, A. N.
    Lavelle, K.
    Kallenbach, L.
    Gillard, P.
    Shah, D.
    Schwedt, T. J.
    HEADACHE, 2022, 62 : 82 - 82
  • [34] Real-world Adherence to Subsequent CGRP mAb Treatment Among Chronic Migraine Patients Initially Treated With OnabotulinumtoxinA: A Retrospective Claims Analysis
    Dong, Yanan
    Gusovsky, Amanda
    Shah, Darshini
    Park, Tae Jin
    Zhao, Changgeng
    TOXICON, 2024, 237 : 22 - 22
  • [35] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Manack Adams, Aubrey
    PAIN AND THERAPY, 2021, 10 (02) : 809 - 826
  • [36] Real-world onabotulinumtoxinA treatment patterns in patients with overactive bladder
    Chughtai, Bilal
    Ricker, Christine N.
    Boldt, Ryan J.
    Elterman, Dean
    NEUROUROLOGY AND URODYNAMICS, 2024, 43 (02) : 396 - 406
  • [37] A Real-World Perspective of Patients With Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States
    Cohen, J. M.
    Pandya, S.
    Krasenbaum, L. J.
    Thompson, S. F.
    Chen, C.
    Tangirala, K.
    HEADACHE, 2020, 60 : 5 - 6
  • [38] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
    Amira Salim
    Elise Hennessy
    Claire Sonneborn
    Olivia Hogue
    Sudipa Biswas
    MaryAnn Mays
    Aarushi Suneja
    Zubair Ahmed
    Ignacio F. Mata
    CNS Drugs, 2024, 38 : 481 - 491
  • [39] Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Mechtler, Laszlo
    Cook, Lisa
    Rhyne, Christopher
    Jenkins, Brian
    Hughes, Olivia
    Dabruzzo, Brett
    Manack Adams, Aubrey
    Diamond, Merle
    PAIN AND THERAPY, 2024, 13 (06) : 1571 - 1587
  • [40] Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
    Scuteri, Damiana
    Tonin, Paolo
    Nicotera, Pierluigi
    Vulnera, Marilu
    Altieri, Giuseppina Cristina
    Tarsitano, Assunta
    Bagetta, Giacinto
    Corasaniti, Maria Tiziana
    TOXINS, 2022, 14 (08)
12345